JP2024512765A5 - - Google Patents

Info

Publication number
JP2024512765A5
JP2024512765A5 JP2023560819A JP2023560819A JP2024512765A5 JP 2024512765 A5 JP2024512765 A5 JP 2024512765A5 JP 2023560819 A JP2023560819 A JP 2023560819A JP 2023560819 A JP2023560819 A JP 2023560819A JP 2024512765 A5 JP2024512765 A5 JP 2024512765A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
administered
cpis
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023560819A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024512765A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/022801 external-priority patent/WO2022212690A1/en
Publication of JP2024512765A publication Critical patent/JP2024512765A/ja
Publication of JP2024512765A5 publication Critical patent/JP2024512765A5/ja
Pending legal-status Critical Current

Links

JP2023560819A 2021-04-01 2022-03-31 トール様受容体アゴニストを使用したがん治療 Pending JP2024512765A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163169674P 2021-04-01 2021-04-01
US63/169,674 2021-04-01
US202263298589P 2022-01-11 2022-01-11
US63/298,589 2022-01-11
PCT/US2022/022801 WO2022212690A1 (en) 2021-04-01 2022-03-31 Cancer therapy using toll-like receptor agonists

Publications (2)

Publication Number Publication Date
JP2024512765A JP2024512765A (ja) 2024-03-19
JP2024512765A5 true JP2024512765A5 (https=) 2025-04-08

Family

ID=83456830

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023560819A Pending JP2024512765A (ja) 2021-04-01 2022-03-31 トール様受容体アゴニストを使用したがん治療

Country Status (7)

Country Link
EP (1) EP4313315A4 (https=)
JP (1) JP2024512765A (https=)
KR (1) KR20240004419A (https=)
AU (1) AU2022249092A1 (https=)
CA (1) CA3215582A1 (https=)
DE (1) DE112022001882T9 (https=)
WO (1) WO2022212690A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024243794A1 (en) * 2023-04-06 2025-11-06 Trisalus Life Sciences, Inc. System and device for providing localized turbulence for delivering a medical embolizing agent

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100881923B1 (ko) 2000-12-27 2009-02-04 다이나박스 테크놀로지 코퍼레이션 면역자극 폴리뉴클레오티드 및 그것의 사용 방법
US20040009151A1 (en) * 2002-04-04 2004-01-15 Kay Mark A. Methods for delivering recombinant adeno-associated virus virions to the liver of a mammal
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
US7963956B2 (en) * 2003-04-22 2011-06-21 Antisense Pharma Gmbh Portable equipment for administration of fluids into tissues and tumors by convection enhanced delivery technique
US8696698B2 (en) 2009-12-02 2014-04-15 Surefire Medical, Inc. Microvalve protection device and method of use for protection against embolization agent reflux
US8500775B2 (en) 2009-12-02 2013-08-06 Surefire Medical, Inc. Protection device and method against embolization agent reflux
US9539081B2 (en) 2009-12-02 2017-01-10 Surefire Medical, Inc. Method of operating a microvalve protection device
US9770319B2 (en) 2010-12-01 2017-09-26 Surefire Medical, Inc. Closed tip dynamic microvalve protection device
US9968740B2 (en) 2014-03-25 2018-05-15 Surefire Medical, Inc. Closed tip dynamic microvalve protection device
PL3240801T3 (pl) * 2014-12-31 2021-06-14 Checkmate Pharmaceuticals, Inc. Skojarzona immunoterapia nowotworów
US20160287839A1 (en) 2015-03-31 2016-10-06 Surefire Medical, Inc. Apparatus and Method for Infusing an Immunotherapy Agent to a Solid Tumor for Treatment
KR20180014009A (ko) * 2015-05-29 2018-02-07 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 cpg-c 유형 올리고뉴클레오티드의 조합
SG11201808913WA (en) * 2016-04-15 2018-11-29 Dynavax Tech Corp Intratumoral administration of particles containing a toll-like receptor 9 agonist and a tumor antigen for treating cancer
US10806893B2 (en) 2017-01-10 2020-10-20 Surefire Medical, Inc. Guiding catheter having shape-retentive distal end
US10588636B2 (en) 2017-03-20 2020-03-17 Surefire Medical, Inc. Dynamic reconfigurable microvalve protection device
US20190298983A1 (en) 2018-01-15 2019-10-03 Surefire Medical, Inc. Injection Port for Therapeutic Delivery
WO2019160866A2 (en) * 2018-02-13 2019-08-22 Checkmate Pharmaceuticals, Inc. Compositions and methods for tumor immunotherapy
US11850398B2 (en) 2018-08-01 2023-12-26 Trisalus Life Sciences, Inc. Systems and methods for pressure-facilitated therapeutic agent delivery
US12433597B2 (en) 2019-06-04 2025-10-07 Trisalus Life Sciences, Inc. Atraumatic occlusive system with compartment for measurement of vascular pressure change
WO2021011496A1 (en) * 2019-07-12 2021-01-21 Oregon Health & Science University Immunotherapeutic constructs and methods of their use
IL294621A (en) * 2020-01-10 2022-09-01 Sbi Biotech Co Ltd Tlr9 agonist oligonucleotides, compositions comprising same and uses thereof
CA3196273A1 (en) * 2020-09-22 2022-03-31 Trisalus Life Sciences, Inc. Cancer therapy using toll-like receptor agonists

Similar Documents

Publication Publication Date Title
Mercadante The use of anti-inflammatory drugs in cancer pain
JP2022531939A5 (https=)
JP2023166388A5 (https=)
JP2002532392A5 (https=)
JP2024518947A5 (https=)
JP2011251975A5 (https=)
Kang et al. In vivo evaluation of oral anti-tumoral effect of 3, 4-dihydroquinazoline derivative on solid tumor
JP2017510579A5 (https=)
NZ598534A (en) Dosage regimen of an s1p receptor modulator
TWI455723B (zh) 納曲酮及安非他酮於治療超重或肥胖病患之用途
JP2023552700A5 (https=)
EP2034980A1 (en) Methods and compositions for the treatment of viral infections
MX2023003041A (es) Métodos para administrar dosis terapéuticas de moléculas de acoplamiento a células t biespecíficas para el tratamiento de cáncer.
JP2019504012A5 (https=)
JP2023514992A5 (https=)
JP2024512765A5 (https=)
AU2013208649A1 (en) Combination therapy for the treatment of cancer
TWI483721B (zh) The use of a composition containing a ferrous amino acid chelate for the manufacture of anti-cancer medicaments
JP2024016209A5 (https=)
JP2008540364A5 (https=)
JP2025148449A5 (https=)
JP2024517085A5 (https=)
JP2021004249A5 (https=)
Park et al. Ticagrelor-induced acute kidney injury can increase serum concentration of statin and lead to concurrence of rhabdomyolysis
JP2023501781A5 (https=)